BIOLASE (OTCPK:BIOL.Q) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BIOL.Q Overzicht aandelen

BIOLASE, Inc. ontwikkelt, produceert, verkoopt en verkoopt samen met haar dochterondernemingen lasersystemen voor tandartsen en hun patiënten in de Verenigde Staten en internationaal.

Over het bedrijf

BIOL.Q fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen betekenisvolle marktkapitalisatie ( $2M )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

+ 1 meer risico

BIOLASE, Inc. Concurrenten

Invacare

OTCPK:IVCR.Q

US$512.8k

Escalon Medical

OTCPK:ESMC

US$1.1m

Electromedical Technologies

OTCPK:EMED

US$314.4k

LogicMark

NasdaqCM:LGMK

US$821.3k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor BIOLASE
Historische aandelenkoersen
Huidige aandelenkoers	US$0.015
52 Week Hoogtepunt	US$1.89
52 Week Laag	US$0.015
Bèta	0.68
11 maand verandering	-74.27%
3 maanden verandering	-83.33%
1 Jaar Verandering	-99.16%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nov 24

Rendement voor aandeelhouders

	BIOL.Q	US Medical Equipment	US Markt
7D	-77.7%	-2.1%	0.3%
1Y	-99.2%	19.4%	32.4%

Rendement versus industrie: BIOL presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 22.6 % opleverde.

Rendement versus markt: BIOL presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is BIOL.Q's price volatile compared to industry and market?
BIOL.Q volatility
BIOL.Q Average Weekly Movement	27.4%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van BIOL is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 19% ) van BIOL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1984	157	John Beaver	www.biolase.com

BIOLASE, Inc. ontwikkelt, produceert, verkoopt en verkoopt samen met haar dochterondernemingen lasersystemen voor tandartsen en hun patiënten in de Verenigde Staten en daarbuiten. De tandheelkundige lasersystemen stellen tandartsen, parodontologen, endodontologen, pediatrische tandartsen, kaakchirurgen en andere tandheelkundige specialisten in staat om een reeks minimaal invasieve tandheelkundige procedures uit te voeren, waaronder cosmetische, restauratieve en complexe chirurgische toepassingen. Het bedrijf biedt Waterlase all-tissue tandheelkundige lasersystemen voor het snijden van zachte en harde weefsels; diode soft-tissue lasersystemen voor zachte weefsels, hygiëne, tijdelijke pijnverlichting, tanden bleken en cosmetische procedures; en Epic Hygiëne laser om niet-chirurgische parodontitis te behandelen en de klinische productie te verbeteren.

BIOLASE, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van BIOLASE zich tot de beurswaarde?
BIOL.Q fundamentele statistieken
Marktkapitalisatie	US$567.26k
Inkomsten(TTM)	-US$26.81m
Inkomsten(TTM)	US$46.10m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is BIOL.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BIOL.Q resultatenrekening (TTM)
Inkomsten	US$46.10m
Kosten van inkomsten	US$30.88m
Brutowinst	US$15.22m
Overige uitgaven	US$42.02m
Inkomsten	-US$26.81m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.73
Brutomarge	33.01%
Nettowinstmarge	-58.15%
Schuld/Eigen Vermogen Verhouding	-631.5%

Hoe presteerde BIOL.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

BIOL.Q Overzicht aandelen

Beloningen

Risicoanalyse

BIOLASE, Inc. Concurrenten

OTCPK:IVCR.Q

US$512.8k

OTCPK:ESMC

US$1.1m

OTCPK:EMED

US$314.4k

NasdaqCM:LGMK

US$821.3k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Motion for Joint Administration Approved for BIOLASE, Inc.

BIOLASE, Inc. Filed for Bankruptcy

The Nasdaq Stock Market to Delist Common Stock of BIOLASE

BIOLASE, Inc. Provides Earnings Guidance for the Year 2024

BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index

Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock

Recent updates

Motion for Joint Administration Approved for BIOLASE, Inc.

BIOLASE, Inc. Filed for Bankruptcy

The Nasdaq Stock Market to Delist Common Stock of BIOLASE

BIOLASE, Inc. Provides Earnings Guidance for the Year 2024

BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index

Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock

Biolase Receives an Additional Staff Determination Letter from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement for Continued Listing Set in Nasdaq Listing Rule 5550(b)

BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024

BIOLASE, Inc. to Report Q1, 2024 Results on May 13, 2024

BIOLASE Receives Staff Determination Letter from Nasdaq Regarding Failure to Meet the Minimum Closing Bid Price Requirement as Required by Listing Rule 5550(a)(2)

BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

BIOLASE, Inc. to Report Q4, 2023 Results on Mar 21, 2024

BIOLASE, Inc., Annual General Meeting, May 02, 2024

BIOLASE Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $7.031795 million.

Nasdaq Grants Extension to BIOLASE, Inc. to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023

BIOLASE, Inc. Provides Earnings Guidance for the Year 2024

Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc

BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial

BIOLASE, Inc. has filed a Follow-on Equity Offering.

BIOLASE Receives Non-Compliance Notice From Nasdaq

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

BIOLASE, Inc. Announces Study Performed by the Independent Mcguire Institute Confirms Positive 12 Month Clinical Outcomes for Biolase Repair(R) Perio Protocol

BIOLASE, Inc. to Report Q3, 2023 Results on Nov 09, 2023

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $4.5 million.

BIOLASE Provides Non-Compliance Update

BIOLASE, Inc. Provides Earnings Guidance for the Second Half of 2023

BIOLASE, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Listing Qualifications Staff of Nasdaq Determines to Delist BIOLASE's Common Stock from the Nasdaq Capital Market and to Suspend Trading of the Common Stock at the Opening of Business on June 20 2023

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. to Report Q1, 2023 Results on May 11, 2023

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

BIOLASE Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

PIPStek LLC Files Patent Infringement Lawsuit Against BIOLASE

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022

BIOLASE, Inc. to Report Q3, 2022 Results on Nov 10, 2022

BIOLASE, Inc. Appoints Russell Morrow as Chief Dental Officer, Effective November 1, 2022

Biolase partners with dental speciality programs across U.S.

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE, Inc. Appoints Steven Sandor to Chief Operating Officer

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

BIOLASE, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

BIOLASE, Inc. Announces Election of Board of Directors

BIOLASE, Inc. to Report Q1, 2022 Results on May 12, 2022

BIOLASE: Bad News Across The Board - Sell

Price target decreased to US$2.13

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021